ABSCI CORP. DL -,0001 Aktie

Absci reports positive interim results from the Phase 1 HEADLINE study for the hair‑loss candidate ABS‑201 without serious adverse events, which led to a sharp share‑price rise on June 24. At the same time, the company agreed a $100 million equity placement involving a pharmaceutical company. The funds are intended to support further development of the antibody therapy. » Plus sur finanzen.net

Absci is gaining investor attention after its AI-designed antibody ABS-201 moved into human clinical testing for androgenetic alopecia, with early safety data from the HEADLINE trial supporting the program. The company highlights its generative AI platform as a driver to accelerate antibody discovery and reduce development costs, with potential applications beyond hair loss including endometriosis. Hedge fund holdings in Absci rose modestly quarter-over-quarter, and bullish commentary frames the stock as benefiting from broader adoption of AI-enabled drug discovery if clinical progress continues. » Plus sur finance.yahoo.com

Absci reported revenue of $215,000 for Q1 2026 versus expected $1.43 million, a negative surprise of 84.97%. Earnings per share of -$0.19 were slightly better than the expectation of -$0.1943. R&D expenses rose 17.7% to $19.3 million; cash stood at $125.7 million and is expected to fund operations into the first half of 2028. Management is focusing on the ABS-201 program, with preliminary proof-of-concept data in H2 2026 and full data in early 2027; the stock reacted only moderately to the results. » Plus sur de.investing.com

Absci reported revenue of $200,000 for Q1 2026, missing the $1.43 million forecast by a wide margin. EPS was -$0.19, slightly better than expected (-$0.1943). R&D expenses rose to $19.3 million, and cash totaled $125.7 million, with a cash runway into mid-2028. The stock fell 3.11% in after-hours trading; management continues to emphasize focus on the development of ABS-201 and on operational efficiency. » Plus sur de.investing.com

Absci shares climbed about 22.2% in early trading to $4.815, driven by positive assessments of the hair-loss treatment market. KeyBanc sees significant market potential of more than $40 billion based on promising study data from competitors like Veradermics and Nektar, and reaffirmed a $9 price target for Absci. Analysts note that Absci’s candidate ABS-201 could be complementary in nature, as the dosing requires only two to three injections over six months. » Plus sur de.investing.com